SYS-Stomach - Gastric Cancer Prevention Project
The SYS-Stomach project seeks to identify predictive response factors to targeted drug therapies for gastric cancer. Using a systems medicine approach, the project aims to identify biomarkers and specific cell differences that can predict a patient's response or resistance to the drugs cetuximab or trastuzumab - with the ultimate goal of improving targeted therapies and patient outcomes. The project builds on the success of the previous CANCERMOTISYS project. However, in contrast to similar projects which rely on omics data only, the SYS-Stomach project assesses both cellular motility and invasiveness phenotypes and uses them to generate biomarkers and computational models, respectively.
The SYS-Stomach project will build a knowledge network that integrates current knowledge on gastric carcinoma, systematic molecular measurements (like epigenetics, gene expression and protein regulations), and all relevant aspects of tumor behavior, including morphology, adhesion, proliferation, metastatic potential, and motility-focused cell phenotype measurements. This semantic knowledge network will be used to build computational models of treatment response and, in combination with biostatistics methods, extract multi-modal patient stratification biomarker profiles. The response predictors will be validated using tumor samples collected from gastric cancer patients treated with either cetuximab or trastuzumab, which will further inform the knowledge network in an iterative process.
The SYS-Stomach project is supported by the German Federal Ministry of Education and Research (BMBF).